E. David Crawford, MD, Editor-in-Chief
LEARNING CENTERS
LATEST CONTENT
Neil H. Baum, MD, discusses the frequency and danger of falls and fractures in older Americans, noting that nocturia is a major cause. He emphasizes the important role urologists play in screening patients for falls, and explains the multifactorial nature of nocturia and corresponding treatment options, as well as how to manage patients’ comorbidities.
Seth P. Lerner, MD, Professor of Urology at Baylor College of Medicine, reviews the results of the Optimized DeLivery of Mitomycin for Primary UTUC Study (OLYMPUS) trial, of which he was the principal investigator. In this study, a thermal, reversible gel was used as a kidney-sparing treatment of low-grade upper tract urothelial cancer (UTUC). He discusses the difficulty of managing UTUC, the function of UGN-101, and the dramatic results in patient outcomes from this trial.
Steven K. Wilson, MD, FACS, FRCS, explores paradigm shifts in the materials and techniques used for inflatable penile prosthesis implants (IPP) and artificial urinary sphincters (AUS). He focuses on how urologists have improved the standard of care through the use of new technology and a clearer understanding of the negative effects of these procedures.
Frances M. Alba, MD, reviews the findings of a survey-based study she conducted to assess the current state of American urology residency programs, which she presented at the 98th Annual Meeting of the South Central Section of the American Urological Association. She emphasizes the importance of research training and scholarly activity for the well-being of residents and faculty, as well as for the overall advancement of urology.
Jennifer M. Taylor, MD, MPH, discusses the factors that led to the current opioid epidemic and the consequences of excessive perioperative opioid prescribing. She then identifies concrete and evidence-based strategies to reduce opioid prescribing and use in particular surgical cases.
A. Edward Yen, MD, discusses the incidence, prognosis, and therapeutic considerations for regionally advanced prostate cancer. He defines the delineation between clinical and pathologic lymph node metastatic prostate cancers and emphasizes the importance of prescribing therapy based on individual risk factors.
Neil F. Mariados, MD, describes the role of genetic mutations in the efficacy of prostate cancer treatment options and in the science behind poly (ADP-ribose) polymerase (PARP) inhibition. He also reviews clinical trials leading to PARP inhibitor research in prostate cancer and the many clinical trials investigating the intersection between cancer genetics and prostate cancer.
